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Abstract
Background: Brain norepinephrine (NE) plays an important role in the modulation of stress response and
neuroinflammation. Recent studies indicate that in Alzheimer’s disease (AD), the tau neuropathology begins in the
locus coeruleus (LC) which is the main source of brain NE. Therefore, we investigated the changes in brain NE system
and also the immune status under basal and stress conditions in transgenic rats over-expressing the human truncated
tau protein.
Methods: Brainstem catecholaminergic cell groups (LC, A1, and A2) and forebrain subcortical (nucleus basalis
of Meynert), hippocampal (cornu ammonis, dentate gyrus), and neocortical areas (frontal and temporal association
cortices) were analyzed for NE and interleukin 6 (IL-6) mRNA levels in unstressed rats and also in rats exposed to single
or repeated immobilization. Moreover, gene expression of NE-biosynthetic enzyme, tyrosine hydroxylase (TH), and
several pro- and anti-inflammatory mediators were determined in the LC.
Results: It was found that tauopathy reduced basal NE levels in forebrain areas, while the gene expression of IL-6 was
increased in all selected areas at the same time. The differences between wild-type and transgenic rats in brain NE and
IL-6 mRNA levels were observed in stressed animals as well. Tauopathy increased also the gene expression of TH in the
LC. In addition, the LC exhibited exaggerated expression of pro- and anti-inflammatory mediators (IL-6, TNFα, inducible
nitric oxide synthases 2 (iNOS2), and interleukin 10 (IL-10)) in transgenic rats suggesting that tauopathy affects
also the immune background in LC. Positive correlation between NE and IL-6 mRNA levels in cornu ammonis in stressed
transgenic animals indicated the reduction of anti-inflammatory effect of NE.
Conclusions: Our data thus showed that tauopathy alters the functions of LC further leading to the reduction of NE
levels and exaggeration of neuroinflammation in forebrain. These findings support the assumption that tau-related
dysfunction of LC activates the vicious circle perpetuating neurodegeneration leading to the development of AD.
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Background
Sporadic Alzheimer’s disease (AD) represents the most
prevalent form of dementia in the elderly, with several
hypotheses being proposed to explain its etiopathogenesis.
These hypotheses have focused either on the role of
amyloid β, hyperphosphorylated and truncated tau protein,
neuroinflammation, altered insulin signalization, impaired
blood-brain barrier permeability, or other related factors
and mechanisms [1, 2]. However, despite such enormous
scientific effort, the primary factors responsible for
the development of AD still remain only vaguely defined.
Recently accumulated evidence indicates that alter-
ation of the brain’s noradrenergic system plays an
important role in the development of AD-related
neuropathology during the early stages of AD. Central
norepinephrine (NE)-synthesizing neurons are located
predominantly in the brainstem, particularly in the locus
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coeruleus (LC). These neurons richly ramify and innervate
structures throughout the neuraxis, providing NE to all
brain and spinal cord structures [3]. NE released from
these neurons reduces neuroinflammation and potentiates
synaptic plasticity and neurogenesis. In addition, NE
modulates energy metabolism, the activity of astrocytes
and microglia, cortical perfusion, and permeability of the
blood-brain barrier [4–7]; all functions impaired in AD
patients. Moreover, recent findings indicate that tau
pathology initially occurs in specific brainstem nuclei,
particularly the LC, and spreads from these nuclei to
the forebrain [8–10]. Therefore, it has been suggested
that the LC may represent the center of AD-related
neuropathology [11].
Based on the abovementioned facts, we investigated
the interrelations between brain NE and markers of neu-
roinflammation in discrete brain areas of both wild-type
as well as in transgenic (SHR72) rats expressing a patho-
logical form of tau protein at basal conditions. However,
since brain NE-synthesizing neurons are activated during
stress, which is implicated in the development of AD
[12–15], we also investigated the effect of both single
and repeated immobilization (IMO) stress on NE and
interleukin 6 (IL-6) mRNA levels in brain structures
known to be involved in AD neuropathology. In our
study, we focused on brainstem catecholaminergic cell
groups (LC, A1, A2) as well as the forebrain structures
innervated by the LC, including cornu ammonis (CA),
dentate gyrus (DG), nucleus basalis of the Meynert (NBM),
and both frontal (FCx) and temporal (TCx) association
cortices. In addition, in the LC, we analyzed gene ex-
pression of the NE-biosynthetic enzyme, and tyrosine




Experiments were performed on 6-month-old male trans-
genic (SHR72) and age-matched wild-type rats of the
same SHR genetic background. The transgenic (SHR72)
animals expressed a fragment of tau protein containing
four C-terminal repeats designed to correspond with the
pathological tau protein found in human AD brains. The
transgenic (SHR72) animals were prepared by microinjec-
tion of human cDNA encoding N- and C-terminal trun-
cated tau protein encompassing the region of amino acids
151–391 into the male pronucleus of 1-day-old rat em-
bryos. The transgenic construct (human truncated MAPT
cDNA under Thy-1 promoter) was devoid of all prokary-
otic sequences before injection. The injected embryos were
incubated in vitro and implanted to the oviducts of pseudo-
pregnant foster mothers about 12 h after the injection. This
animal model recapitulates basic features of human neuro-
fibrillary pathology typical of AD sufferers and is the unique
transgenic model that unequivocally demonstrates that
expression of pathologically truncated tau protein is suffi-
cient to drive neuropathology typical of AD [16–18].
The homozygous transgenic (SHR72) animals with
eight copies of the transgene per genome only survived
to the age of 4 months. Therefore, we bred hemizygous
transgenic (SHR72) animals with wild-type animals of
the same genetic background, which expanded the life-
span of transgenic (SHR72) animals to an average of
7 months. The transgene was transmitted to subsequent
generations according to Mendelian law, and the colony
was phenotypically stable at the time the animals used in
this study were taken (12th generation).
The animals, bred at the Institute of Neuroimmunology,
were kept under controlled conditions in the animal
facility (12-h light/12-h dark cycle, lights on/off at
0600 hours; temperature, 22 ± 1 °C) with free access
to tap water and standard pelleted rat chow. All experi-
ments were performed between 0800 and 1200 hours,
with all external noises or any other stressful stimuli of
the animals being strictly avoided. The experiments were
carried out in accordance with the Council Directive
2010/63EU of the European Parliament and the Council
of 22 September 2010 on the protection of animals used
for scientific purposes.
Immobilization stress
In the experiments, we used unstressed (control) and
stressed groups of wild-type and transgenic (SHR72) rats
(Fig. 1):
(a)Control groups (C): unstressed animals (n = 9 of
both wild-type and transgenic rats) that were
decapitated immediately after being taken out from
their home cages.
(b)Single IMO group (1×IMO): the animals (n = 9 of
both wild-type and transgenic rats) that were
subjected once to 2 h IMO and were decapitated
immediately after the end of stressor exposure.
(c)Repeated IMO group (7×IMO): the animals (n = 10
of both wild-type and transgenic rats) were subjected
repeatedly to IMO for 2 h daily for seven successive
days and decapitated immediately after the last IMO
was finished.
(d)Adapted IMO group (6×IMO + 24 h): the animals
(n = 10 of both wild-type and transgenic rats) were
subjected to IMO for 2 h daily for six successive
days and decapitated 24 h after the last IMO, at the
time when the seventh IMO would have been
finished. This group enables to determine the effect
of seventh exposure to IMO in repeatedly stressed
rats and therefore to investigate the mechanisms of
adaptation to chronic stress. The IMO stress was
performed as previously described [19].
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Microdissection of brain areas
The tissue of brainstem catecholaminergic cell groups as
well as that of the forebrain subcortical and cortical
areas (Fig. 2) was dissected bilaterally by the micropunch
technique [20] according to the original punching guide
atlas [21]. Briefly, after the quick removal, the brains were
immediately frozen on dry ice and cut into 300-μm-thick
serial coronal sections using a cryostat (Reichert-Jung)
at −10 °C. The tissue was isolated under a dissection
microscope by specialized metal punching needles with a
diameter ranging from 600 to 1200 μm (for details, see
Fig. 2) and then stored at −70 °C for the later analyses.
Determination of catecholamine in brain areas
Tissues of isolated brain areas were sonicated in 100 μL
of 0.01 M HCl. Two microliters of homogenate were
used for the determination of proteins using a bicinchoni-
nic acid (BCA) protein assay (Thermo Scientific, Rockford,
IL.). The appropriate amount of supernatant (containing
10–400 μg of protein, depending on brain area) was used
for norepinephrine measurement using 3-CAT Research
RIA kits (Labor Diagnostica Nord, Nordhorn, Germany)
according to the manufacturer’s protocol. We have tested
this method for different brain areas, and we obtained
a good linearity of measurements between 10 and
800 pg of NE or 10 and 400 μg protein in homogenates.
The final loading amounts of homogenates were LC and
NBM, 10–20 μg of protein; A1 and A2 noradrenergic cell
groups, 20–30 μg of protein; temporal cortex, 100–200 μg
of protein; frontal cortex, 300–400 μg of protein; and CA,
300–400 μg of protein. The sensitivity of the RIA assay
for NE in the brain tissue was 7.2 pg/sample making it
sensitive enough for the performed experiments. The
values were normalized to proteins determined in the
homogenate and expressed as nanograms of catecholamine
per milligram of protein.
Isolation of RNA and measurement of mRNA levels by
RT-PCR
Total RNA was isolated from the frozen tissue samples
of the brain areas using TRI REAGENT (MRC, Inc.).
Reverse transcription was performed from total RNA using
Ilustra™ Ready-To-Go™ RT-PCR beads (GE Healthcare,
Buckinghamshire, UK) with pd(N)6 primer according to
manufacturer’s protocol.
Gene expression was determined by RT-PCR analyses.
For all PCR amplifications, cDNA aliquots containing
20 ng of total RNA were used. Transcripts were amplified
with specific primers (shown in Table 1) using a SensiFast
Hi-ROX qPCR Kit (Bioline, Taunton, MA) according to
the manufacturer’s instructions in 20 μL of total reaction
volume using an ABI Prism 7900HT Sequence Detection
System thermocycler (Applied Biosystems, Inc, Foster
City, CA, USA). Data were analyzed with sodium dodecyl
sulfate (SDS) software version 2.3 (Applied Biosystems)
and inspected to determine artifacts (loading errors,
threshold errors, etc.). Count numbers (Ct values) were
exported to an Excel spreadsheet and analyzed according
to the ΔΔCT method described by Livak and Schmittgen
[22]. For internal controls, several genes were tested in-
cluding 18S rRNA, beta tubulin, GAPDH, TATA-binding
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Fig. 1 Schematic illustration of experimental design. a Control group. b Single immobilization group (1×IMO). c Repeated immobilization group
(7×IMO). d Adapted IMO group (6×IMO+24 h)
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of the investigated genes to these internal controls and
found similar results regarding both gene expression
changes and patterns. Subsequently, we examined the
variability of values between samples within experimental
groups and concluded that 18S rRNA would be the most
appropriate internal control.
Western blot analysis
For detection of TH protein, freshly frozen brain sam-
ples were homogenized in ice-cold extraction buffer
(20 mM Tris-HCl, pH 8, 100 mM NaCl, 1 mM EDTA,
1 mM dithiothreitol, 0.5 % Triton X-100, 20 mM NaF,







Fig. 2 Localization of brainstem catecholaminergic cell groups (LC, A1, and A2) and forebrain areas in the rat brain (a-f) and diameters of
punching needles used for their microdissections. Axons of A1 and A2 noradrenergic cell groups are a part of the ascending ventral
noradrenergic bundle (VNB) innervating hypothalamus. Axons of the locus coeruleus (LC/A6) cell group constitute the ascending dorsal
noradrenergic bundle (DNB) providing noradrenergic innervation of hippocampal cornu ammonis (CA) and dentate gyrus (DG), nucleus basalis of
the Meynert (NBM), as well as frontal (FCx) and temporal cortex (TCx). Red circles norepinephrine synthesizing cell groups. Blue circles forebrain
structures innervated by the locus coeruleus. Modified according to [23, 48, 49]
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inhibitor cocktail (Complete without EDTA; Roche,
Manheim, Germany) using the disposable polypropylene
homogenizers fitted to the tip of 1.5 mL eppendorf tube
(E&K Scientific Products, CA, USA). The samples were
centrifuged for 20 min at 16,000×g, and supernatants were
transferred into new tubes. Concentrations of total pro-
teins were measured by PierceTM BCA protein assay kit
(Thermo Scientific, USA). Samples were mixed with
standard 2× sample loading buffer (10 mM Tris-HCl, 4 %
SDS, 4 % 2-mercaptoethanol, 20 % glycerol, and 0.1 %
Coomassie Brilliant Blue G-250) and heated at 95 °C for
5 min. Twenty micrograms of total protein was then sepa-
rated by electrophoresis in 12 % SDS-polyacrylamide gels.
Separated proteins were transferred onto nitrocellulose
membranes (Whatman, Maidstone, UK), which were
blocked in Odyssey blocking buffer (LI-COR, Lincoln,
NE, USA) containing 0.1 % Tween 20 (Sigma, St. Louis,
MO, USA). Membranes were incubated overnight with pri-
mary monoclonal antibody (anti-TH, MAB5280, Millipore,
dilution 1:3000) in Odyssey blocking buffer (LI-COR,
Lincoln, NE, USA) containing 0.1 % Tween 20 (Sigma, St.
Louis, MO, USA). Secondary infrared 800 CW goat
anti-mouse IgG (LI-COR, Lincoln, NE, USA) was diluted
1:10,000 in Odyssey blocking buffer (LI-COR, Lincoln,
NE, USA) containing 0.1 % Tween 20 (Sigma, St. Louis,
MO, USA) and incubated with membrane for 2 h at RT.
The blots were scanned with Odyssey infrared imaging
system (LI-COR, Lincoln, NE, USA). Detected bands
were quantified using Image Studio software ver. 2.0.38
(LI-COR, Lincoln, NE, USA).
Statistical analysis
All statistical analyses were performed using SigmaPlot
11.0 (Systat Software, Inc., Germany). The normal distri-
bution of the quantitative data was verified for all ana-
lyzed data using the Kolmogorov-Smirnov test allowing
for parametric tests to be applied. Statistical analysis of
the data was performed by t test (used for the compari-
son of changes in NE and IL-6 mRNA levels between
unstressed wild-type and transgenic rats; Fig. 3) and by
one-way ANOVA measurement followed by a Dunnett’s
test (used for the comparison of changes in NE levels as
well as in mRNA levels of TH and cytokines in rats
exposed to a single or repeated immobilization; Figs. 4,
5, 6, 7, and 8). The correlation between NE levels and
IL-6 mRNA levels was determined by linear regression test
(Fig. 9). The results are expressed as means ± SEM
and represent an average of four to ten animals. A P value
of <0.05 was taken as indicative of statistical significance
for the tests.
Results
Effect of tauopathy on basal norepinephrine and IL-6
mRNA levels in brainstem and forebrain areas
Tauopathy significantly affected basal levels of NE as
well as gene expression of IL-6, one of the major pro-
inflammatory cytokines in the brain (Fig. 3). Although
NE levels were not considerably changed in the brain-
stem catecholaminergic cell groups, they were clearly
decreased in all forebrain structures innervated by the
LC, particularly in hippocampal areas such as the CA
and DG, as well as NBM, FCx, and TCx in transgenic
(SHR72) animals compared to wild-type rats (P < 0.05;
Fig. 3a). On the other hand, basal levels of IL-6 mRNA
were elevated in all abovementioned investigated areas,
the most prominent elevation being observed in the LC
and DG of transgenic rats (P < 0.01; Fig. 3b).
These data led us to further study the question of
whether the tauopathy itself affects NE and IL6 mRNA
levels in the investigated brain areas of transgenic rats
under the conditions of single and repeated stress by
immobilization.
Effect of tauopathy on stress-induced changes of
norepinephrine levels in brainstem and forebrain areas
We found that in stressed rats, there were differences in
NE levels within selected brain structures between the
wild-type and transgenic groups. In general, in stressed
transgenic rats, the concentrations of NE remained un-
changed compared to their unstressed, transgenic controls.
In the LC, a significant reduction of NE concentration
was found in wild-type animals exposed to either single
or repeated IMO (P < 0.05; Fig. 4a). However, transgenic
animals did not show this stress-induced reduction in
NE levels (Fig. 4a). Furthermore, we did not find any
Table 1 Sequences of primers used for amplification of target
cDNA of interleukin 6 (IL-6), tyrosine hydroxylase (TH), tumor
necrosis factor alpha (TNF-α), inducible nitric oxide synthases 2
(iNOS2), interleukin 10 (IL-10), transforming growth factor beta 1
(TGFβ1), and 18S ribosomal protein















Mravec et al. Journal of Neuroinflammation  (2016) 13:15 Page 5 of 17
significant changes in NE concentrations within the A1
noradrenergic cell group when examining singly or re-
peatedly stressed wild-type and transgenic rats (Fig. 4c).
But, the A2 noradrenergic cells group showed a non-
significant reduction in NE levels in both wild-type and
transgenic animals exposed to single IMO (Fig. 4e).
We found that NE levels were reduced in both hippo-
campal regions (CA and DG) compared to wild-type ani-
mals in both the single (P < 0.01) and repeatedly stressed
(P < 0.01) transgenic rats as well as in transgenic rats
from the adapted IMO group (P < 0.05). Whereas repeated
IMO non-significantly increased NE levels in the CA and
DG of wild-type rats the NE levels remained unchanged
or were even non-significantly reduced in transgenic rats
when compared to controls (Fig. 5a, c).
Although we have seen significantly reduced NE
levels in the FCx of transgenic compared to wild-type rats
(P < 0.01, single and repeatedly stressed rats; P < 0.05,
adapted IMO rats; Fig. 6a), we found no difference in the
levels of NE levels in the TCx between stressed transgenic
and wild-type rats (Fig. 6c). Whereas repeated stress
non-significantly increased NE levels in the FCx of
wild-type rats, NE levels did not change or were even
non-significantly reduced in transgenic rats when com-
pared to controls. Additionally, NE levels in the TCx were
unchanged, while reduced NE levels were found in
the entorhinal cortex (data not shown).
Repeated stress non-significantly increased NE levels
in the NBM of wild-type rats. In transgenic rats, NE
levels remained unchanged when compared to those of
unstressed transgenic animals, but they were signifi-
cantly lower than these in repeatedly stressed wild-type
rats (P < 0.01; Fig. 6e).
Effect of tauopathy on stress-induced changes of IL-6
mRNA levels in brainstem and forebrain areas
Both, single as well as repeated exposure to IMO stress
induced a significant elevation of IL-6 mRNA level in
Norepinephrine




































































Fig. 3 Basal levels of norepinephrine (NE) and interleukine-6 mRNA (IL-6 mRNA) in brainstem catecholaminergic cell groups containing NE cell
bodies (LC, A1, A2) and forebrain subcortical and cortical areas in wild-type (white square) and transgenic (SHR72) rats (black square). Each value is
the mean ± SEM (n = 4–10). Statistical significance vs. corresponding wild-type group: *P < 0.05; **P < 0.01
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Fig. 4 Levels of norepinephrine (NE) and interleukine-6 mRNA (IL-6 mRNA) in the LC, A1, and A2 brainstem noradrenergic areas in wild-type
(white square) and transgenic (SHR72) rats (black square) exposed to a single (1 × 2 h) or repeated (7 × 2 h) immobilization stress (IMO). C control
rats; 6×IMO + 24 h-adapted IMO rats exposed to 6×IMO for 2 h and decapitated 24 h after the last IMO. Each value is the mean ± SEM (n = 5–8).
Statistical significance vs. corresponding wild-type group: *P < 0.05; **P < 0.01; statistical significance vs. wild-type control group: #P < 0.05; ##P < 0.01
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the LC (P < 0.01, single stress; P < 0.05; adapted IMO
and repeated stress; Fig. 4b) and A1 noradrenergic cell
group (P < 0.05 single and repeated stress; Fig. 4d) of
wild-type animals, However, IL-6 mRNA levels were
only elevated in wild-type animals by repeated stress in
the A2 noradrenergic cell group (P < 0.01; Fig. 4f ), CA
(P < 0.01; Fig. 5b), and FCx (P < 0.05; Fig. 6b).
Similar to the abovementioned findings of NE levels in
stressed transgenic rats, exposure of rats to IMO did not
induce further increases in IL-6 gene expression in se-
lected brain areas of transgenic animals when compared
to values found in unstressed transgenic animals (Figs. 4,
5, and 6). However, in some brainstem and in hippocam-
pal areas, IL-6 mRNA levels were significantly elevated
in stressed transgenic rats compared to corresponding
wild-type groups (Figs. 4d, e, and 5b, d).
Effect of tauopathy on basal and stress-induced changes
of TH gene expression and TH protein levels in brainstem
noradrenergic cell groups
Brainstem noradrenergic neurons, particularly these
in the LC, provide NE to all levels of the neuraxis.
Reduced NE levels and increased levels of IL-6
mRNA in investigated forebrain structures (Fig. 3a, b)
indicate altered function of brainstem noradrenergic
neurons. Therefore, when attempting to assess the
functionality of the LC, we selected TH mRNA and
protein levels as markers of NE synthesis. We also
investigated the effect of stress on gene expression
and protein levels of TH.
Repeated IMO significantly increased TH mRNA
levels in LC of wild-type rats (P < 0.05; Fig. 7a). This is
not surprising as TH gene expression in the LC of
Norepinephrine














































































































Fig. 5 Levels of norepinephrine (NE) and interleukine-6 mRNA (IL-6 mRNA) in the cornu ammonis (CA) and dentate gyrus (DG) in wild-type (white square)
and transgenic (SHR72) rats (black square) exposed to a single (1 × 2 h) or repeated (7 × 2 h) immobilization stress (IMO). C control; 6×IMO+ 24 h-adapted
IMO rats exposed to 6×IMO for 2 h and decapitated 24 h after the last IMO. Each value is the mean ± SEM (n = 5–8). Statistical significance vs.
corresponding wild-type group: *P < 0.05; **P < 0.01; statistical significance vs. wild-type control group: #P < 0.05; ##P < 0.01; statistical significance vs.
transgenic control group: +P < 0.05
Mravec et al. Journal of Neuroinflammation  (2016) 13:15 Page 8 of 17
Norepinephrine















































































































































Nucleus basalis of Meynert
Fig. 6 Levels of norepinephrine (NE) and interleukine-6 mRNA (IL-6 mRNA) in frontal cortex, temporal cortex, and nucleus basalis of Meynert in
wild-type (white square) and transgenic (SHR72) rats (black square) exposed to a single (1 × 2 h) or repeated (7 × 2 h) immobilization stress (IMO).
C control; 6×IMO + 24 h-adapted IMO rats exposed to 6×IMO for 2 h and decapitated 24 h after the last IMO. Each value is the mean ± SEM
(n = 4–10). Statistical significance vs. corresponding wild-type group: *P < 0.05; **P < 0.01; statistical significance vs. wild-type control group: #P < 0.05
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transgenic rats was already significantly increased in un-
stressed (P < 0.05) as well as in singly stressed transgenic
rats when compared to corresponding wild-type animals
(P < 0.05; Fig. 7a). Also, non-significantly increased TH
mRNA levels were observed in repeatedly stressed trans-
genic rats (Fig. 7a). These stress-induced increases of TH
in transgenic rats were confirmed by similar results found
in TH protein levels (Fig. 7c).
We also investigated TH gene expression in the A1
and A2 noradrenergic cell groups. We found that TH
mRNA levels in the A1 noradrenergic cell group of wild-
type animals were significantly elevated only by repeated
IMO stress (P < 0.05; Fig. 7b). When compared to wild-
type animals, transgenic rats showed elevated basal
levels (P < 0.05), but no further elevation was detected
after either single or repeated stress (Fig. 7b). Similarly
to the A1 noradrenergic cell group, gene expression of
TH in the A2 noradrenergic cell group of wild-type ani-
mals was significantly elevated only by repeated IMO
stress (P < 0.05; Fig. 7d).
In transgenic rats, stress did not induce any sig-
nificant changes in TH mRNA levels. Similarly, no
changes were seen when comparing the values of
TH mRNA levels in the A2 noradrenergic cell groups









































































WT TG WT TG WT TG WT TG
6xIMO C 1xIMO 7xIMO
1.96   1.93   1.00   1.38   1.38  1.42   1.56   1.80A.U.
Fig. 7 Gene expression (a, b, and d) and protein (c) levels of tyrosine hydroxylase (TH) in the LC, A1, and A2 brainstem noradrenergic cell groups
of wild-type (white square) and transgenic (SHR72) rats (black square) exposed to a single (1 × 2 h) or repeated (7 × 2 h) immobilization stress
(IMO). Each sample of TH protein represents a pool of two to three animals (c), values are expressed as arbitrary units (A.U.) calculated as a ratio
between TH and GAPDH in a given sample. C control; 6×IMO + 24 h-adapted IMO rats exposed to 6×IMO for 2 h and decapitated 24 h after the
last IMO. Each value is the mean ± SEM (n = 5–8; a, b, and d). Statistical significance vs. corresponding wild-type group: *P < 0.05; statistical
significance vs. wild-type control group: #P < 0.05
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Effect of tauopathy on basal and stress-induced changes
of levels of pro- and anti-inflammatory factors in the
locus coeruleus
In transgenic rats, tauopathy is localized mainly to the
brainstem [16]. Because tauopathy also induces neuroin-
flammation, we also investigated levels of selected pro-
and anti-inflammatory factors as markers of the immune
milieu of the LC.
Besides IL-6 mRNA, we determined in the LC expres-
sion of genes of other inflammatory factors, particularly
the tumor necrosis factor alpha (TNF-α), inducible nitric
oxide synthases 2 (iNOS2), interleukin 10 (IL-10), and
transforming growth factor beta 1 (TGFβ1). Whereas
mRNA levels of the pro-inflammatory factor TNF-α
were only non-significantly elevated in unstressed trans-
genic rats (P = 0.078; Fig. 8a), the expression of the
iNOS2 gene showed significant increases in the LC of
transgenic animals during basal conditions (P < 0.01;
Fig. 8c). However, after the exposure to repeated stress,
TNF-α mRNA levels were reduced compared to corre-
sponding wild-type rats (P < 0.05; Fig. 8a), while gene ex-
pression of iNOS2 was significantly reduced in repeatedly
stressed transgenic rats when compared to unstressed
transgenic rats (P < 0.05; Fig. 8c).
Gene expression of the anti-inflammatory cytokine
IL-10 was significantly elevated during basal conditions in
the LC of transgenic rats (P < 0.01; Fig. 8b). Even if stress
had no effect on IL-10 mRNA levels in transgenic rats,
gene expression of IL-10 was significantly elevated in both
singly stressed and adapted IMO transgenic rats when
compared to values found in corresponding wild-type
animals (P < 0.05; Fig. 8b).
Gene expression of neuroprotective factor TGFβ1 in
wild-type animals was not affected by stress. However,
TGFβ1 mRNA levels were significantly lower in repeat-
edly stressed and adapted IMO transgenic rats compared
TNF-α mRNA










































































































Fig. 8 Gene expression of pro-inflammatory factors TNF-α (a), iNOS2 (c), and anti-inflammatory factors IL-10 (b) and TGFβ1 (d) in the LC of wild-type
(white square) and transgenic (SHR72) rats (black square) exposed to a single (1 × 2 h) or repeated (7 × 2 h) immobilization stress (IMO). C control;
6×IMO+ 24 h-adapted IMO rats exposed to 6×IMO for 2 h and decapitated 24 h after the last IMO. Each value is the mean ± SEM (n = 5–8). Statistical
significance vs. corresponding wild-type group: *P < 0.05; **P < 0.01; statistical significance vs. wild-type control group: #P < 0.05, ##P < 0.01
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to levels found in the corresponding wild-type animals
(P < 0.05; Fig. 8d).
Effect of tauopathy on correlation between
norepinephrine and IL-6 mRNA levels in cornu ammonis
under basal and stress conditions
The reduced NE and elevated IL-6 mRNA levels found
in unstressed transgenic rats (Fig. 3), differences in NE
and IL-6 mRNA levels in stressed transgenic animals
(Figs. 4, 5, and 6), and altered immune background in
the LC (Fig. 8) indicate the effect of deregulated immu-
nomodulation on the brain’s noradrenergic system.
Therefore, we investigated the effect of stress in both
wild-type and transgenic rats on the relationship be-
tween NE and IL-6 mRNA levels in the CA, a brain
structure innervated almost exclusively by the LC.
We did not find any correlation between NE and IL-6
mRNA levels in the CA of either unstressed or stressed
wild-type (Fig. 9a, c) or transgenic rats (Fig. 9b, d). How-
ever, whereas NE levels are similar between unstressed
wild-type and transgenic rats (ranging from 0.7 to
1.5 ng/mg of protein), the mean gene expression of IL-6 is
almost three times higher in transgenic rats (Fig. 9a, b).
Discussion
The brain’s noradrenergic system regulates the central
stress response [23] and maintains several cognitive,
affective, and behavioral functions [3, 24], while contrib-
uting to the consolidation of learning and memory [25].
However, Gibbs and Summers showed that NE released
by brainstem noradrenergic neurons, besides its neuro-
transmitter role, is also involved in maintaining the
Fig. 9 Correlation plots illustrating the relationship of norepinephrine (NE) concentration and interleukine-6 mRNA (IL-6 mRNA) in cornu ammonis
(CA) of wild-type controls (a, white circle), transgenic controls (b, black circle), wild-type rats exposed to a single 2-h immobilization stress (c, white circle),
and transgenic rats exposed to a single 2-h immobilization stress (d, black circle)
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brain’s tissue milieu [4]. Furthermore, centrally released
NE modulates synaptic plasticity, neurogenesis, energy
metabolism, activity of astrocytes and microglia, cortical
perfusion, and the permeability of the blood-brain barrier
[4–7]. Moreover, it also exerts several potent anti-in-
flammatory and anti-oxidative effects on the brain tissue
[26]. All of the abovementioned “homeostatic” processes
modulated by NE are impaired in the brains of AD pa-
tients. Importantly, recent findings of Braak et al. [9] indi-
cate that in humans, pathological tau species are originally
formed in the LC (the brainstem structure representing
the main accumulation of noradrenergic neurons in the
brain) and then spread by axonal transport and interneur-
onal communications to the transentorhinal region, then
to the entorhinal region, the hippocampal formation, and
then later to the association cortices [9]. Therefore, it is
suggested that the LC plays a crucial role in the develop-
ment of AD-related neuropathology [11]. The importance
of the LC in AD development is further supported by the
finding that LC destruction results in the worsening of
neuroinflammation and amyloid β deposition in brains of
transgenic Aβ animal models, as well as in elevated IL-1β
and Ccl2 cytokines in laboratory animals [27, 28]. Interest-
ingly, monoaminergic deficiency and severe depletion of
NE has been found in most LC projection areas in AD
patients [29]. Morphological studies of brains of AD pa-
tients have shown that the LC undergoes significant
degeneration that precedes pathological changes in the
forebrain [30]. It is suggested that this degeneration starts
early in the course of AD pathogenesis and that the
LC represents the centre from which altered tau proteins
spread throughout the forebrain structures [9]. Therefore,
we investigated the effect of tauopathy on the LC by using
transgenic (SHR72) rats that over-express human trun-
cated tau protein [17].
Preclinical investigation of the LC role in AD pathogen-
esis is based mainly on the study of the effects resulting
from the destruction of this noradrenergic cell group on
the development of AD-related neuropathology. However,
in the available literature, information on tauopathy’s
effect on LC functions and on the immune background of
brain tissue during basal and stress conditions is lacking.
Based on the abovementioned facts, we investigated
the mutual relationship between the brain’s noradrener-
gic system and immune activity in unstressed and singly
or repeatedly stressed wild-type and transgenic rats that
over-express human truncated tau protein [17]. Here, we
demonstrate for the first time that expression of human
truncated tau protein, whose primary sequence was
derived from paired helical filaments obtained from the
brains of AD patients, is sufficient to induce dysfunction
of LC neurons in vivo and this dysfunction is most likely
followed by exaggerated synthesis of pro-inflammatory
cytokines in brain structures innervated by the LC
that are known to be affected by neuropathology in
AD patients.
We have found significant reduction of basal NE levels
in hippocampus (CA and DG) and NBM as well as in
cortical areas (frontal and temporal association cortex)
of transgenic rats, structures innervated almost entirely
by noradrenergic LC neurons [3]. Our findings indicate
that the function of the noradrenergic system in the
brains of transgenic rats is significantly impaired, at least
at the level of NE synthesis. This is in agreement with
observed significant reductions of NE levels on the cere-
brospinal fluid of AD patients compared to matched
controls [31].
Recent studies have revealed that NE exerts a potent
anti-inflammatory effect on the brain [32]. In support of
this, decreased cerebral NE levels and exacerbated neu-
roinflammatory processes have been demonstrated in
murine AD models [27, 33]. Moreover, it is suggested
that the reduction of LC noradrenergic neurons in the
brains of AD patients could be one factor responsible
for the exaggerated neuroinflammation in the brains of
these patients [34]. Based on these facts and assump-
tions, the question has been raised as to whether the re-
duction of brain’s tissue NE levels in transgenic (SHR72)
rats is accompanied by altered immune status in the
brain of these animals. Therefore, we analyzed the gene
expression of IL-6, one of the main immune system fac-
tors in the brain [35]. In transgenic rats, we found a sig-
nificant elevation of IL-6 mRNA in CA, DG, and FCx.
Moreover, significantly elevated IL-6 mRNA levels were
also found in the brainstem, particularly in the LC, A1,
and A2 noradrenergic cell groups. Increased gene ex-
pression of IL-6 in forebrain structures may reflect the
reduced anti-inflammatory effect of NE due to reduced
NE concentrations in these forebrain areas, while the
increased IL-6 mRNA levels in brainstem noradrenergic
areas may result from the burden of tau pathology, as
it is localized mainly in the brainstem of transgenic
(SHR72) rats [16].
It is suggested that stress represents important factor
participating in the development of AD (for review, see
[12]). Moreover, AD-related neuropathology may affect
the stress response as well [36]. Because the LC repre-
sents a key structure modulating stress responses in the
brain [23] and that we found that tauopathy impairs LC
function, we investigated the effect of single and repeated
stress on tissue levels of NE against the background of
tauopathy. Interestingly, the exposure of transgenic rats to
stress did not significantly affect NE levels when compared
to unstressed transgenic animals. However, in the CA,
DG, FCx, and NBM, NE levels in transgenic animals were
significantly lower when compared to the NE levels of
corresponding wild-type groups. These findings indicate
that tauopathy reduces noradrenergic neurotransmission
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not only at basal conditions but also in animals exposed to
stressors. Furthermore, these reduced NE levels in the
forebrain areas of stressed, transgenic rats were accom-
panied by elevated gene expression of IL-6 in the CA and
DG. Moreover, IL-6 mRNA levels were also elevated in
brainstem A1 noradrenergic cells of stressed, transgenic
animals. These findings indicate that the immune milieu
remains altered in investigated brain areas in stressed,
transgenic rats, but stress is not able to significantly affect
gene expression of IL-6. It can be speculated that exposure
to immobilization stress daily for 7 days is not sufficient to
alter the immune status of transgenic rats and therefore
longer period of chronic stress exposure will be necessary
to determine the effect of stress on neuroinflammation at
the background of tauopathy.
In transgenic (SHR72) rats, tau pathology is predomin-
antly found in the brainstem [16]. However, even if re-
duced NE levels in forebrain areas of transgenic rats
indicate functional impairment of the LC, we did not
find any neurodegenerative changes at the level of the
LC morphology (unpublished data). Using immunohisto-
chemistry, we found accumulation of tau pathology in
the form of AT8-immunopositive tau, pre-tangles, and
neurofibrillary tangles in brainstem areas that innervate
the LC, particularly in the paragigantocellular nucleus
and hypoglossal preposite nucleus (unpublished data).
Neurons of the paragigantocellular nucleus project to
the LC and increase noradrenergic neurotransmission in
many forebrain areas, including the hippocampus, via
mostly glutamatergic excitatory fibers [37]. Therefore,
we speculate that in transgenic (SHR72) rats, the tauopa-
thy found in the paragigantocellular nucleus attenuates
glutamatergic neurotransmission from the LC, which con-
sequently reduces levels of NE in forebrain structures.
However, alternative mechanisms may participate in the
impairment of the LC as well, including reduced axonal
transport of trophic factors to the nuclei of LC neurons
from structures innervated by the LC.
To further investigate the functional impairment of
the LC, we determined gene expression and protein
levels of TH, the rate-limiting enzyme of NE biosyn-
thesis as TH mRNA levels reflect changes in activity of
the noradrenergic cells in this brain area [23]. We de-
tected a significant increase of TH mRNA in the LC of
repeatedly stressed wild-type animals that is in accord-
ance with our previous reports [23, 38–41]. Importantly,
TH protein concentration in the LC is in good agree-
ment with TH expression. When compared to wild-type
rats, transgenic (SHR72) animals started from the higher
basal levels of TH mRNA, but did not show any signifi-
cant changes after stress exposure. Increased TH levels
in transgenic rats indicate exaggerated NE biosynthesis.
However, as discussed above, NE levels in forebrain
areas innervated by the LC were reduced. There is
published data showing that even if the number of LC
neurons in the brain of AD patients is significantly re-
duced, the remaining LC neurons undergo significant
compensatory changes [42]. Our contradictory findings
indicate that even if compensatory mechanisms in nor-
adrenergic neurotransmission machinery are activated at
the level of the LC, these responses are not able to com-
pensate for the functional deficits manifested by reduced
NE concentrations in brain areas innervated by the LC.
Besides the LC, we also analyzed TH mRNA in other
noradrenergic cell groups that participate in noradrener-
gic innervation of forebrain structures, particularly in
the A1 and A2 noradrenergic cell groups. However, in
contrast to the LC, the A1 and A2 noradrenergic cell
groups predominantly innervate the hypothalamus [23].
Therefore, sparse information is available as to how
neurofibrillary pathology affects these cell groups. We
found that TH mRNA levels in wild-type animals were
significantly elevated in A1 and A2 noradrenergic cell
groups after repeated stress. Also, while TH mRNA in
A1 noradrenergic cells group of transgenic rats started
from elevated basal levels, no further changes were de-
tected after either single or repeated stress. We suggest
that similarly to LC, increased TH expression in the A1
noradrenergic cell group might represent a compensa-
tory response to impairment of TH-positive A1 neurons
in this transgenic (SHR72) animal model of tauopathy.
However, AD-related neuropathology of A1 noradrener-
gic neurons has not yet been described in available lit-
erature. However, we found that the A2 noradrenergic
cell group shows an increase of TH mRNA levels in
repeatedly stressed wild-type animals not seen in trans-
genic rats. Because the A1 and A2 noradrenergic cell
groups innervate mainly the hypothalamic nuclei, we
also investigated changes in NE level in the hypothal-
amic paraventricular nucleus. Importantly, in contrast to
significantly reduced NE levels in forebrain structures
innervated by the LC, we found that NE levels were only
non-significantly reduced in the hypothalamic paraven-
tricular nucleus in transgenic rats (9.93 ± 0.94 ng/mg pro-
tein) compared to wild-type animals (16.38 ± 2.57 ng/mg
protein). These findings indicate that tauopathy in trans-
genic (SHR72) rats affects predominantly noradrenergic
neurotransmission in the hippocampus, nucleus basalis of
Meynert, and association cortices, all of which are areas
innervated by the LC and affected in AD patients.
To further to determine the mechanisms responsible
for tau-related alteration of the LC in transgenic
(SHR72) rats, we measured tissue mRNA levels of
both pro- and anti-inflammatory factors, including TNF-α,
iNOS2, IL-10, and TGFβ1. We found that gene expression
of these factors differs between wild-type and transgenic
rats at both basal and stressed conditions, although TNF-α
mRNA levels in unstressed, transgenic rats were only
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non-significantly increased. However, even if gene ex-
pression of TNF-α declined in repeatedly stressed trans-
genic rats compared to unstressed transgenic rats, TNF-α
mRNA in rats exposed to repeated stress was significantly
elevated compared to the matched, wild-type group. Gene
expression of iNOS2, another pro-inflammatory factor,
was significantly increased at basal conditions and findings
related to gene expression of TNF-α and iNOS2 indicate a
pro-inflammatory milieu in the LC tissue of transgenic
rats. Moreover, gene expression of the anti-inflammatory
cytokine IL-10 was increased in unstressed transgenic rats
as well as in transgenic animals exposed to a single stres-
sor, indicating activation of compensatory immune mech-
anisms at the level of the LC against a background of
tauopathy. Comparison of NE, IL-6 mRNA, TNF-α
mRNA, and IL-10 mRNA in the LC of transgenic rats in-
dicate that the anti-inflammatory effect of NE in the LC is
impaired. Because tauopathy is localized predominantly to
the brainstem of transgenic (SHR72) rats, several local fac-
tors may promote an inflammatory milieu in the LC as
well. Reduced gene expression of the neuroprotective fac-
tor TGFβ1 in repeatedly stressed transgenic rats highlights
impairment of neuroprotective mechanisms in the LC.
Based on the abovementioned findings, we suggest that
tauopathy affects function of brainstem nuclei innervating
the LC and alters the brainstem immune milieu. These
alterations might participate in neuroinflammation and
the reduced neuroprotection in the LC accompanied by
reduced release of NE by LC neurons into the forebrain
areas of transgenic (SHR72) rats. Reduced NE release
might then participate in the development of neuroinflam-
mation in forebrain structures innervated by the LC.
To investigate the role of the LC dysfunction in ob-
served alteration of immune milieu in forebrain areas of
transgenic rats, we assessed the correlation between NE
and IL-6 mRNA levels in both wild-type and transgenic
rats at basal and stress conditions. Importantly, we found
that even if there was no correlation between NE and IL-6
mRNA levels at basal conditions, transgenic rats exhibit
approximately threefold higher IL-6 mRNA levels. These
findings indicate that the inhibitory effect of brain NE
on neuroinflammation is severally impaired against a
background of tauopathy. However, the mechanisms and
pathways responsible for this phenomenon need further
investigation.
It is necessary to note that all abovementioned param-
eters (e.g., interleukins) were investigated in brain tissues
obtained by microdissection (punching) technique. How-
ever, this method does not allow to determine whether
alterations are present in neurons, glia, or both types of
cells. Therefore, for more complex view of neuropatho-
logical consequences of tau pathology on the function of
the LC and on neuroinflammation, other approaches
(e.g., immunohistochemistry) must be used.
Conclusions
Our data have shown that tau pathology in the brains of
transgenic (SHR72) rats alters central noradrenergic
neurotransmission, particularly in brain’s structures inner-
vated by noradrenergic neurons, under basal conditions as
well as after an exposure to single or chronic stress. We
observed increases in IL-6 gene expression in brain struc-
tures that may reflect a reduced anti-inflammatory effect-
iveness of the LC noradrenergic system. Importantly, some
in vitro and in vivo studies have provided evidence that
increases in NE levels can attenuate AD-related neuro-
pathology and neuroinflammation, while enhancing cogni-
tion [43, 44]. In support of this, some clinical studies have
already confirmed that pharmacotherapy potentiating
noradrenergic neurotransmission is able to improve cogni-
tive symptoms, while reducing depression and aggression
in AD patients [45–47].
However, it is necessary to note that it remains unclear
whether tauopathy in transgenic (SHR72) rats affect LC
neurons directly or indirectly. Indirect mechanisms of
altered LC function in transgenic rats may include (i)
impaired transport of trophic factors from brainstem
structures affected by tauopathy to the LC and (ii) re-
duced synthesis of norepinephrine in varicosities of the
LC neurons as a result of either the pro-inflammatory
milieu or other mechanisms. Moreover, tauopathy in
transgenic (SHR72) rats may also potentially affect other
catecholaminergic cell groups, exaggerating the norad-
renergic deficit followed by impairment of the brain mi-
lieu and development of neuropathology. However, it is
unclear whether other monoaminergic cell groups are
affected in this transgenic model, and therefore, this
needs further investigation.
Based on our data, we suggest that transgenic rats of this
study can be efficiently employed in detailed investigation
of molecular mechanisms of neuronal degeneration related
to tauopathy, neuroinflammation, and, more importantly,
in the development of disease modifying strategy for
treatment of Alzheimer’s disease and other tauopathies.
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